RNA Therapeutics Delivery: Why It Remains Difficult
RNA therapeutics delivery remains difficult because the molecule itself is unstable, the body clears or misroutes many delivery systems before they reach the right cells, and most of the RNA that does get inside cells still fails to escape endosomes into the cytosol. You can make RNA potent in a dish, but turning that potency into reliable, safe activity in patients is still one of the hardest problems in drug delivery.
If you want to understand where the field stands, you need more than the usual line that “delivery is the bottleneck.” You need to see how chemistry, cell biology, immunology, tissue targeting, and dose tolerance all collide in one development problem. This article walks you through the main reasons delivery stays hard, why liver-directed success has not translated cleanly to other organs, and what separates simple uptake from real functional delivery.
What Makes RNA Therapeutics So Hard To Deliver In The First Place?
You are starting with a payload that works against you on several fronts. RNA is large, negatively charged, and vulnerable to ribonucleases, which means it does not cross cell membranes well and does not remain intact for long without chemical modification or a protective carrier. That basic physical reality is why naked messenger ribonucleic acid, small interfering ribonucleic acid, or many oligonucleotides rarely produce useful systemic activity on their own. Read More
Comments
Post a Comment